Gender-specific characteristics of atherosclerosis in menopausal women: Risk factors, clinical course and strategies for prevention

Climacteric

Volumn 10, Issue SUPPL. 2, 2007, Pages 16-20

  Vitale, C ^a   Miceli, M ^a   Rosano, G M C ^a  

^a IRCCS SAN RAFFAELE PISANA   (Italy)

Author keywords

Atherosclerosis; Gender; Menopause; Prevention; Risk factors

Indexed keywords

CHOLESTEROL;

ACUTE CORONARY SYNDROME; ANGINA PECTORIS; ATHEROSCLEROSIS; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR FUNCTION; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONFERENCE PAPER; DEVELOPING COUNTRY; DIABETES MELLITUS; DISEASE COURSE; GLUCOSE METABOLISM; HORMONE SUBSTITUTION; HUMAN; HYPERTENSION; ISCHEMIA; ISCHEMIC HEART DISEASE; MENOPAUSE; MORBIDITY; MORTALITY; PRIORITY JOURNAL; PROPHYLAXIS; RISK FACTOR; SEX DIFFERENCE; SYMPTOM;

AGED; ATHEROSCLEROSIS; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; HYPERTENSION; MALE; MENOPAUSE; MIDDLE AGED; PRIMARY PREVENTION; RISK FACTORS; RISK REDUCTION BEHAVIOR; SEX DISTRIBUTION; UNITED STATES; WOMEN'S HEALTH;

EID: 34548859563     PISSN: 13697137     EISSN: 14730804     Source Type: Journal    
DOI: 10.1080/13697130701602712     Document Type: Conference Paper

References (15)

1. Rosano GM, Fini M. Postmenopausal women and cardiovascular risk: impact of hormone replacement therapy. Cardiol Rev 2002;10:51-60
2. Assmann G, Schulte H. The importance of triglycerides: results from the Prospective Cardiovascular Munster (PROCAM) Study. Eur J Epidemiol 1992;8(Suppl 1):99-103
3. De Aloysio D, Gambacciani M, Meschia M, et al. The effect of menopause on blood lipid and lipoprotein levels. Atherosclerosis 1999;147:147-53
4. Bass KM, Newschaffer CJ, Klag MJ, Bush TL. Plasma lipoprotein levels as predictors of cardiovascular death in women. Arch Intern Med 1993;153:2209-16
5. Hu G, Qiao Q, Tuomilehto J, Eliasson M, Feskens EJ, Pyorala K; DECODE Insulin Study Group. Plasma insulin and cardiovascular mortality in non-diabetic European men and women: a meta-analysis of data from eleven prospective studies. Diabetologia 2004;47:1245-56
6. Lindheim SR, Presser SC, Ditkoff EC, Vijod MA, Stanczyk FZ, Lobo RA. A possible bimodal effect of estrogen on insulin sensitivity in postmenopausal women and the attenuating effect of added progestin. Fertil Steril 1993;60:664-7
7. Ferrannini E, Natali A, Capaldo B, Lehtovirta M, Jacob S, Yki-Jarvinen H. Insulin resistance, hyperinsulinemia, and blood pressure: role of age and obesity. European Group for the Study of Insulin Resistance (EGIR). Hypertension 1997;30:1144-9
8. Practice Guidelines For Primary Care Physicians: 2003 ESH/ESC Hypertension Guidelines. J Hypertens 2003;21:1779-86
9. Gambacciani M, Ciapponi M, Cappagli B, Canussi B, De Simone L, Genazzani AR. Climacteric modifications in body weight and fat tissue distribution. Climacteric 1999;2:37-44
10. Reunanen A, Suhonen O, Aromaa A, Knekt P, Pyorala K. Incidence of different manifestations of coronary heart disease in middle-aged Finnish men and women. Acta Med Scand 1985;218:19-26
11. National Cholesterol Education Program. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA 1993;269:3015-23
12. Guidelines for using serum cholesterol, highdensity lipoprotein cholesterol, and triglyceride levels as screening tests for preventing coronary heart disease in adults. American College of Physicians. Part 1. Ann Intern Med 1996;124:515-17
13. Ridker PM, Cook NR, Lee IM, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 2005;352:1293-304
14. Grodstein F, Manson JE, Stampfer MJ, Willett WC. The discrepancy between observational studies and randomized trials of menopausal hormone therapy. Ann Intern Med 2004;140:764-5
15. Rubig A. Drospirenone: a new cardiovascularactive progestin with antialdosterone and antiandrogenic properties. Climacteric 2003;6(Suppl 3):49-54